studies

breast cancer - HER2-positive, lapatinib plus capecitabine vs. HER inhibitor, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsNALA, 2020 (REV) 1.14 [0.93; 1.39] NALA (brain metastases), 2020 (REV) 1.11 [0.73; 1.70] 1.13[0.95; 1.35]NALA, 2020 (REV), NALA (brain metastases), 2020 (REV)20%722moderatenot evaluable progression or deaths (PFS)detailed resultsNALA, 2020 (REV) 1.32 [1.08; 1.60] NALA (brain metastases), 2020 (REV) 1.52 [0.95; 2.42] 1.34[1.12; 1.61]NALA, 2020 (REV), NALA (brain metastases), 2020 (REV)20%722moderatenot evaluable DORdetailed resultsNALA, 2020 (REV) 2.00 [1.34; 2.99] NALA (brain metastases), 2020 (REV) 2.13 [0.53; 8.51] 2.01[1.36; 2.96]NALA, 2020 (REV), NALA (brain metastases), 2020 (REV)20%722moderatenot evaluable objective responses (ORR)detailed resultsNALA (brain metastases), 2020 (REV) 0.98 [0.36; 2.70] 0.98[0.36; 2.70]NALA (brain metastases), 2020 (REV)10%74NAnot evaluable Anaemia AE (grade 3-4)detailed resultsNALA (brain metastases), 2020 (REV) 2.06 [0.07; 62.92] 2.06[0.07; 62.92]NALA (brain metastases), 2020 (REV)10%99NAnot evaluable Asthenia AE (grade 3-4)detailed resultsNALA (brain metastases), 2020 (REV) 3.20 [0.32; 31.83] 3.20[0.32; 31.83]NALA (brain metastases), 2020 (REV)10%99NAnot evaluable Back pain AE (grade 3-4)detailed resultsNALA (brain metastases), 2020 (REV) 1.02 [0.02; 52.48] 1.02[0.02; 52.48]NALA (brain metastases), 2020 (REV)10%99NAnot evaluable Constipation AE (grade 3-4)detailed resultsNALA (brain metastases), 2020 (REV) 1.02 [0.02; 52.48] 1.02[0.02; 52.48]NALA (brain metastases), 2020 (REV)10%99NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsNALA (brain metastases), 2020 (REV) 1.02 [0.06; 16.79] 1.02[0.06; 16.79]NALA (brain metastases), 2020 (REV)10%99NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsNALA (brain metastases), 2020 (REV) 0.40 [0.13; 1.26] 0.40[0.13; 1.26]NALA (brain metastases), 2020 (REV)10%99NAnot evaluable Fatigue AE (grade 3-4)detailed resultsNALA (brain metastases), 2020 (REV) 1.02 [0.14; 7.55] 1.02[0.14; 7.55]NALA (brain metastases), 2020 (REV)10%99NAnot evaluable Headache AE (grade 3-4)detailed resultsNALA (brain metastases), 2020 (REV) 1.02 [0.02; 52.48] 1.02[0.02; 52.48]NALA (brain metastases), 2020 (REV)10%99NAnot evaluable Nausea AE (grade 3-4)detailed resultsNALA (brain metastases), 2020 (REV) 1.57 [0.25; 9.80] 1.57[0.25; 9.80]NALA (brain metastases), 2020 (REV)10%99NAnot evaluable Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)detailed resultsNALA (brain metastases), 2020 (REV) 1.02 [0.31; 3.42] 1.02[0.31; 3.42]NALA (brain metastases), 2020 (REV)10%99NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsNALA (brain metastases), 2020 (REV) 2.06 [0.07; 62.92] 2.06[0.07; 62.92]NALA (brain metastases), 2020 (REV)10%99NAnot evaluable Rash AE (grade 3-4)detailed resultsNALA (brain metastases), 2020 (REV) 2.06 [0.07; 62.92] 2.06[0.07; 62.92]NALA (brain metastases), 2020 (REV)10%99NAnot evaluable Stomatitis AE (grade 3-4)detailed resultsNALA (brain metastases), 2020 (REV) 2.06 [0.07; 62.92] 2.06[0.07; 62.92]NALA (brain metastases), 2020 (REV)10%99NAnot evaluable Vomiting AE (grade 3-4)detailed resultsNALA (brain metastases), 2020 (REV) 1.02 [0.06; 16.79] 1.02[0.06; 16.79]NALA (brain metastases), 2020 (REV)10%99NAnot evaluable Weight decreased AE (grade 3-4)detailed resultsNALA (brain metastases), 2020 (REV) 1.02 [0.06; 16.79] 1.02[0.06; 16.79]NALA (brain metastases), 2020 (REV)10%99NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-06-28 11:35 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 336,147,145,355,337,146,317 - treatments: 1312